The effect of ongoing illicit drug use on HIV treatment remains controversial, especially in countries where access to HIV treatment for active injection drug users (IDUs) is limited because of presumed non-adherence. We sought to investigate the influence of drug use patterns on adherence to antiretroviral therapy and virological suppression among IDUs.
Methods
Using generalized estimating equation logistic regression, we explored the effect of abstinence versus ongoing drug use on adherence and virological suppression using data from a community-recruited cohort of IDUs in Vancouver (BC, Canada).
Results
A total of 381 HIV-positive IDUs were included in this analysis, among whom the median follow-up time was 30 months. In a multivariate model, no relationship was found between abstinence (reference) and active injection (adjusted odds ratio [AOR] 0.88, 95% confidence interval [CI] 0.65–1.17) and non-injection (AOR 0.97, 95% CI 0.67–1.41) drug use with adherence. In sub analyses, ongoing injection drug use was associated with a lower odds of virological suppression in comparison to abstinence (AOR 0.74, 95% CI 0.57–0.97; P=0.026) and both active IDUs and active non-IDUs had lower odds of virological suppression compared with abstinent participants when longer periods of virological suppression were considered.
Conclusions
Given the absence of a strong relationship between abstinence and ongoing drug use and adherence among HIV-positive IDUs, programmes that restrict antiretrovirals to abstinent individuals should be re-examined. The lower rates of virological suppression associated with ongoing drug use nevertheless highlight the importance of comprehensive systems of care and addiction treatment for active drug users.
References
1.
HammerS.M., SquiresK.E., HughesM.D.A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less.N Engl J Med1997; 337: 725–733.
2.
CASCADE Collaboration.Determinants of survival following HIV-1 seroconversion after the introduction of HAART.Lancet2003; 362: 1267–1274.
3.
HoggR.S., YipB., KullyC.Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.CMAJ1999; 160: 659–665.
4.
MocroftA., LedergerberB., KatlamaC.Decline in the AIDS and death rates in the EuroSIDA study: an observational study.Lancet2003; 362: 22–29.
5.
WoodE., MontanerJ.S., TyndallM.W., SchechterM.T., O'ShaughnessyM.V., HoggR.S.II. Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy.J Infect Dis2003; 188: 1164–1170.
6.
BruceR.D., AlticeF.L.Clinical care of the HIV-infected drug user.Infect Dis Clin North Am2007; 21: 149–179.
7.
WoodE., MontanerJ.S., YipB.Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.CMAJ2003; 169: 656–661.
8.
VlahovD., CelentanoD.D.Access to highly active antiretroviral therapy for injection drug users: adherence, resistance, and death.Cad Saude Publica2006; 22: 705–718.
9.
ChanderG., HimelhochS., MooreR.D.Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy.Drugs2006; 66: 769–789.
10.
PatersonD.L., SwindellsS., MohrJ.Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.Ann Intern Med2000; 133: 21–30.
11.
WoodE., HoggR.S., YipB., HarriganP.R., O'ShaughnessyM.V., MontanerJ.S.Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/l.Ann Intern Med2003; 139: 810–816.
12.
PalepuA., TyndallM., YipB., O'ShaughnessyM.V., HoggR.S., MontanerJ.S.Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use.J Acquir Immune Defic Syndr2003; 32: 522–526.
13.
WoodE., MontanerJ.S.Antiretroviral therapy: a key part of the public health response to injection drug use.Addiction2008; 103: 660–661.
14.
ArnstenJ.H., DemasP.A., GrantR.W.Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users.J Gen Intern Med2002; 17: 377–381.
15.
RouxP., CarrieriM.P., VillesV.The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.Addiction2008; 103: 1828–1836.
16.
LucasG.M., CheeverL.W., ChaissonR.E., MooreR.D.Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection.J Acquir Immune Defic Syndr2001; 27: 251–259.
17.
WeberR., HuberM., RickenbachM.Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study.HIV Med2009; 10: 407–416.
18.
JordanM.R., LaH., NguyenH.D.Correlates of HIV-1 viral suppression in a cohort of HIV-positive drug users receiving antiretroviral therapy in Hanoi, Vietnam.Int J STD AIDS2009; 20: 418–422.
19.
PalepuA., TyndallM.W., JoyR.Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.Drug Alcohol Depend2006; 84: 188–194.
20.
WoodE., HoggR.S., KerrT., PalepuA., ZhangR., MontanerJ.S.Impact of accessing methadone on the time to initiating HIV treatment among antiretroviral-naive HIV-infected injection drug users.AIDS2005; 19: 837–839.
21.
StrathdeeS.A., PalepuA., CornelisseP.G.Barriers to use of free antiretroviral therapy in injection drug users.JAMA1998; 280: 547–549.
22.
Low-BeerS., YipB., O'ShaughnessyM.V., HoggR.S., MontanerJ.S.Adherence to triple therapy and viral load response.J Acquir Immune Defic Syndr2000; 23: 360–361.
23.
PalepuA., YipB., MillerC.Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use.AIDS2001; 15: 423–424.
24.
WoodE., HoggR.S., LimaV.D.Highly active antiretroviral therapy and survival in HIV-infected injection drug users.JAMA2008; 300: 550–554.
25.
HoggR.S., HeathK., BangsbergD.Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up.AIDS2002; 16: 1051–1058.
26.
BangsbergD.R.Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression.Clin Infect Dis2006; 43: 939–941.
27.
ShuterJ., SarloJ.A., KanmazT.J., RodeR.A., ZingmanB.S.HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%.J Acquir Immune Defic Syndr2007; 45: 4–8.
28.
WoodE., MontanerJ., BraitsteinP.Elevated rates of antiretroviral treatment discontinuation among HIV-infected injection drug users: implications for drug policy and public health.Int J Drug Policy2004; 15: 133–138.
29.
LiangK., ZegerS.Longitutinal data analysis using generalized linear models.Biometrika1986; 73: 13–22.
30.
KerrT., MarshallA., WalshJ.Determinants of highly active antiretroviral therapy discontinuation among injection drug users.AIDS Care2005; 17: 539–549.
31.
ShahN.G., CelentanoD.D., VlahovD.Correlates of enrollment in methadone maintenance treatment programs differ by HIV-serostatus.AIDS2000; 14: 2035–2043.
32.
RothmanJ.K., GreenlandS.Modern Epidemiology. New York: Lippincot Williams & Wilkins1998.
33.
MaldonadoG., GreenlandS.Simulation study of confounder-selection strategies.Am J Epidemiol1993; 138: 923–936.
34.
LimaV.D., GellerJ., BangsbergD.R.The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART.AIDS2007; 21: 1175–1183.
35.
LimaV.D., KopecJ.A.Quantifying the effect of health status on health care utilization using a preference-based health measure.Soc Sci Med2005; 60: 515–524.
36.
KerrT., PalepuA., BarnessG.Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.Antivir Ther2004; 9: 407–414.
37.
RouxP., CarrieriM.P., CohenJ.Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.Clin Infect Dis2009; 49: 1433–1440.
38.
SambamoorthiU., WarnerL.A., CrystalS., WalkupJ.Drug abuse, methadone treatment, and health services use among injection drug users with AIDS.Drug Alcohol Depend2000; 60: 77–89.
39.
HinkinC.H., BarclayT.R., CastellonS.A.Drug use and medication adherence among HIV-1 infected individuals.AIDS Behav2007; 11: 185–194.
40.
ArnstenJ.H., DemasP.A., FarzadeganH.Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring.Clin Infect Dis2001; 33: 1417–1423.
41.
GrossbergR., ZhangY., GrossR.A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV.J Clin Epidemiol2004; 57: 1107–1110.
42.
GrossR., BilkerW.B., WangH., ChapmanJ.How long is the window of opportunity between adherence failure and virologic failure on efavirenz-based HAART?HIV Clin Trials2008; 9: 202–206.
43.
WeiserS.D., FernandesK.A., BrandsonE.K.The association between food insecurity and mortality among HIV-infected individuals on HAART.J Acquir Immune Defic Syndr2009; 52: 342–349.
44.
O'ConnorP.G., SelwynP.A., SchottenfeldR.S.Medical care for injection-drug users with human immunodeficiency virus infection.N Engl J Med1994; 331: 450–459.
45.
CofrancescoJ.Jr., ScherzerR., TienP.C.Illicit drug use and HIV treatment outcomes in a US cohort.AIDS2008; 22: 357–365.
46.
LucasG.M., GriswoldM., GeboK.A., KerulyJ., ChaissonR.E., MooreR.D.Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy.Am J Epidemiol2006; 163: 412–420.
47.
TyndallM.W., McNallyM., LaiC.Directly observed therapy programmes for anti-retroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes.Int J Drug Policy2007; 18: 281–287.
48.
BangsbergD.R., HechtF.M., ClagueH.Provider assessment of adherence to HIV antiretroviral therapy.J Acquir Immune Defic Syndr2001; 26: 435–442.
49.
BangsbergD., TulskyJ.P., HechtF.M., MossA.R.Protease inhibitors in the homeless.JAMA1997; 278: 63–65.
50.
BangsbergD.R., MossA.When should we delay highly active antiretroviral therapy?J Gen Intern Med1999; 14: 446–448.
51.
WoodE., HoggR.S., YipB.Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use.AIDS2005; 19: 1189–1195.
52.
LertF., KazatchkineM.D.Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview.Int J Drug Policy2007; 18: 255–261.
53.
Des JarlaisD.C., PaoneD., MillikenJ.Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial.Lancet1999; 353: 1657–1661.
